title: Second malignancies following treatment for Hodgkin's disease: a Greek experience.
abstract: The risk and the type of second malignancies (SM) developing in 217 treated Hodgkin's disease (HD) patients were studied. The median age of the patients was 35 years (range 14-83) and the M/F ratio 1.8. Treatment consisted of radiotherapy alone (24 patients, 11%), chemotherapy alone (96 patients, 44.3%), or a combination of both modalities (43 patients, 19.8%), while 54 patients (24.9%) received salvage treatment. The median follow-up time was 67 months (range 12-224). Ten patients developed a SM with a 5-year and 10-year actuarial risk of 3.3% and 5.4%, respectively. There were 3 cases of ANLL and MDS (actuarial risk of 2.4% at 6 years), 1 case of non-Hodgkin's lymphoma and 6 cases of solid tumors (actuarial risk of 2.4% at 6 years). The risk of developing SM was higher in males and older patients (> 40 years). SM represent a serious late side effect of successful treatment for HD. The possibility of developing a SM must be taken into consideration in the initial treatment of the disease.
authors.affiliation: Second Department of Internal Medicine-Propaedeutic, Athens University, Evangelismos Hospital, Greece.
authors.forename: T
authors.initials: T
authors.lastname: Economopoulos
authors.forename: N
authors.initials: N
authors.lastname: Stathakis
authors.forename: C
authors.initials: C
authors.lastname: Alexopoulos
authors.forename: N
authors.initials: N
authors.lastname: Pavlidis
authors.forename: M
authors.initials: M
authors.lastname: Constantinidou
authors.forename: E
authors.initials: E
authors.lastname: Briassoulis
authors.forename: E
authors.initials: E
authors.lastname: Papageorgiou
authors.forename: J
authors.initials: J
authors.lastname: Dervenoulas
authors.forename: V
authors.initials: V
authors.lastname: Pappa
authors.forename: M
authors.initials: M
authors.lastname: Vaslamatzis
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D005500:Follow-Up Studies; D006115:Greece; D006689:Hodgkin Disease / Q000473:pathology / Q000628:therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D016609:Neoplasms, Second Primary / Q000209:etiology*